Group 1 - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (00728) at 71.84%, Green Power Environmental (01330) at 69.15%, and China Shenhua (01088) at 68.07% [1] - The latest holding ratio rankings for the top 20 companies show significant ownership levels, with companies like Kaisa New Energy (01108) and COSCO Shipping Energy (01138) also exceeding 67% [1] - The recent five trading days saw Alibaba-W (09988) leading in increased holdings with a rise of 143.50 billion, followed by Yingfu Fund (02800) with an increase of 41.59 billion [1][2] Group 2 - The companies with the largest decreases in holdings over the last five trading days include Meituan-W (03690) with a reduction of 12.14 billion, Great Wall Motors (02333) with a decrease of 8.01 billion, and Xiaomi Group-W (01810) with a drop of 7.57 billion [2] - Other notable companies experiencing significant reductions in holdings include Tencent Holdings (00700) and Li Auto-W (02015), with decreases of 4.65 billion and 4.06 billion respectively [2] - The data reflects a dynamic trading environment, with substantial shifts in investor sentiment towards various companies within the Hong Kong market [2]

Key Points - The top three stocks with net inflow of southbound funds are Alibaba-W (09988) with 5.278 billion, Yingfu Fund (02800) with 2.782 billion, and Hang Seng China Enterprises (02828) with 1.566 billion [1] - The top three stocks with net outflow of southbound funds are Xiaomi Group-W (01810) with -0.721 billion, Innovent Biologics (01801) with -0.466 billion, and Pop Mart (09992) with -0.458 billion [1] - In terms of net inflow ratio, Yuexiu Transportation Infrastructure (01052) leads with 63.76%, followed by Crystal International (02232) with 56.34%, and China Resources Gas (01193) with 53.63% [1] - The stocks with the highest net outflow ratio include QuanFeng Holdings (02285) at -59.36%, Yadea Group (01585) at -54.53%, and TCL Electronics (01070) at -54.28% [1] Net Inflow Rankings - The top ten stocks by net inflow include Alibaba-W (09988) with 5.278 billion, Yingfu Fund (02800) with 2.782 billion, and Hang Seng China Enterprises (02828) with 1.566 billion [2] - Other notable stocks in the net inflow list are Meituan-W (03690) with 0.670 billion and Southern Hang Seng Technology (03033) with 0.620 billion [2] Net Outflow Rankings - The top ten stocks by net outflow include Xiaomi Group-W (01810) with -0.721 billion, Innovent Biologics (01801) with -0.466 billion, and Pop Mart (09992) with -0.458 billion [2] - Other significant stocks in the net outflow list are Li Auto-W (02015) with -0.298 billion and China Construction Bank (00939) with -0.254 billion [2] Net Inflow Ratio Rankings - The top three stocks by net inflow ratio are Yuexiu Transportation Infrastructure (01052) at 63.76%, Crystal International (02232) at 56.34%, and China Resources Gas (01193) at 53.63% [3] - Additional stocks with high net inflow ratios include China Ship Leasing (03877) at 49.13% and Jiangsu Ninghu Expressway at 45.49% [3] Net Outflow Ratio Rankings - The stocks with the highest net outflow ratios include QuanFeng Holdings (02285) at -59.36%, Yadea Group (01585) at -54.53%, and TCL Electronics (01070) at -54.28% [3] - Other notable stocks with significant net outflow ratios are Kangji Medical (09997) at -53.77% and QiuTai Technology (01478) at -47.17% [3]

Market Overview - The Hang Seng Index (HSI) closed at 26,797.18, down by 111.21 points or 0.41% on September 17 [1] - The index reached a high of 26,915.65 and a low of 26,708.53 during the trading session, with a trading volume of 112 million shares [1] Major Blue-Chip Stocks Performance - HSBC Holdings closed at HKD 108.373, up by 1.66% compared to the Hong Kong close [2] - Tencent Holdings closed at HKD 661.407, down by 0.01% compared to the Hong Kong close [2] Stock Price Movements - Tencent Holdings (00700) saw an increase of HKD 16.500, or 2.56%, with an ADR price of HKD 661.407, showing a slight decline of HKD 0.093 compared to the Hong Kong market [3] - Alibaba Group (09988) increased by HKD 8.100, or 5.28%, with an ADR price of HKD 161.550, down by HKD 0.050 [3] - Other notable movements include: - Meituan (03690) up by HKD 4.900, or 4.89% [3] - Baidu Group (09888) up by HKD 17.800, or 15.72% [3] - Kuaishou (01024) up by HKD 2.650, or 3.51% [3]

Group 1 - A total of 395 foreign institutions have participated in A-share listed company research since the beginning of the second half of the year, with a cumulative research count of 1,782 times as of September 16 [1] - Point72 has conducted the most research, with 59 instances, while Goldman Sachs, Bank of America Securities, and Citigroup have each exceeded 40 research instances [1] Group 2 - Key sectors attracting foreign institutional attention include industrial machinery, electrical equipment, electronic instruments, and medical care equipment [3] - Companies such as Estun, Huaming Equipment, Opto, Tianfu Communication, Lens Technology, United Imaging, Mindray, and BeiGene have received research from over 50 foreign institutions [3] - Estun's recent investor relations activity indicates that foreign institutions like Merrill Lynch, Citigroup, Morgan Stanley, BNP Paribas, Deutsche Bank, and Point72 are focused on the demand situation in downstream industries, with Estun expecting continued growth in automotive, electronics, and lithium battery sectors [3] - United Imaging has reported that its AI-driven smart operation system has significantly improved efficiency and reduced costs, supporting its long-term development in the global medical imaging industry [3] - Many foreign institutions believe that the A-share market currently offers rich investment opportunities, particularly in the technology and pharmaceutical sectors [3] - Morgan Stanley recently highlighted areas to watch in the A-share market, including AI computing and applications, innovative drugs, new energy (benefiting from policy adjustments), semiconductors, new consumption, resource products, and high-end manufacturing [3]

Core Insights - The Chinese innovative drug sector has become a hot area in the capital market this year, driven by the real demand for high-quality innovative drugs from domestic patients, which is seen as the core driver for industry recovery [1] Group 1: Market Performance - In the first half of this year, 21 innovative drug companies listed on A-shares achieved a revenue of 28.69 billion yuan, a year-on-year increase of approximately 42%, while 32 innovative drug companies listed on H-shares reported a revenue of 42.13 billion yuan, a year-on-year increase of about 10% [2] - Leading companies have shown particularly strong performance, with Heng Rui Medicine's innovative drug sales revenue reaching 7.57 billion yuan, a year-on-year increase of approximately 14.5% [2] - Innovative drugs from Bai Jie Shen Zhou, such as Bai Yue Ze and Bai Ze An, reported sales of 1.192 billion yuan and 2.643 billion yuan respectively, with year-on-year growth rates of 36.5% and 20.6% [2] Group 2: Policy and Market Dynamics - The Chinese innovative drug market is entering a dual development cycle with domestic medical insurance and overseas markets, leading to a gradual path to profitability for companies [2] - Since its establishment in 2018, the National Medical Insurance Bureau has included 149 innovative drugs in the medical insurance catalog through seven rounds of adjustments, significantly optimizing the clinical medication structure [3] - By May 2025, the medical insurance fund is expected to pay a cumulative 410 billion yuan for negotiated drugs, driving related drug sales to exceed 600 billion yuan [3] Group 3: Future Outlook - The innovative drug market in China is projected to reach a scale of 162 billion yuan by 2024, with medical insurance payments accounting for approximately 43.8% [4] - The commercial success of innovative drugs is seen as a starting point for higher-level research and development, with many companies increasing their R&D investments despite revenue growth [4] - China currently holds a 30% share in global drug research and development, with 1,775 first-in-class drug pipelines, representing 19% of the global total [4]

Group 1 - On September 15, BeiGene's stock increased by 1.40%, with a trading volume of 2.1 billion yuan [1] - The financing data shows that on the same day, BeiGene had a financing purchase amount of 241 million yuan and a financing repayment of 231 million yuan, resulting in a net financing purchase of 10.32 million yuan [1] - As of September 15, the total balance of margin trading for BeiGene was 1.334 billion yuan, with a financing balance of 1.314 billion yuan, accounting for 3.57% of the circulating market value, which is above the 90th percentile level over the past year [1] Group 2 - As of June 30, the number of BeiGene shareholders was 23,300, a decrease of 3.90% from the previous period, while the average circulating shares per person increased by 4.11% to 4,976 shares [2] - For the first half of 2025, BeiGene achieved operating revenue of 17.518 billion yuan, a year-on-year increase of 46.03%, and a net profit attributable to shareholders of 450 million yuan, up 115.63% year-on-year [2] - In terms of institutional holdings, as of June 30, 2025, the top ten circulating shareholders included several notable funds, with changes in their holdings indicating varying levels of investment interest [2]

Market Overview - The Hang Seng Index (HSI) closed at 26,457.88, up by 11.32 points or 0.04% as of September 15, 16:00 Eastern Time [1] - The index reached a high of 26,527.24 and a low of 26,435.55 during the trading session, with an average price of 26,481.40 [1] - The trading volume was 71.35 million shares, indicating active market participation [1] Major Blue-Chip Stocks Performance - HSBC Holdings closed at HKD 108.054, reflecting an increase of 1.46% compared to the Hong Kong closing price [2] - Tencent Holdings closed at HKD 644.822, with a slight increase of 0.21% from the Hong Kong closing price [2] - Alibaba Group (ADR) saw a price of HKD 153.679, down by 0.921 compared to its Hong Kong price, despite a 2.32% increase in its latest price [3] - Other notable performances include BYD Company, which rose by 3.44% to HKD 108.100, and Xiaomi Group, which increased by 1.90% to HKD 56.200 [3] Summary of Stock Movements - Tencent Holdings remained stable with no change in its latest price [3] - HSBC Holdings showed a minor increase of 0.19% [3] - Alibaba's stock experienced a decline when compared to its ADR price [3] - The overall performance of major blue-chip stocks was mixed, with some stocks like BYD and Xiaomi showing positive movements while others like China Ping An and AIA Group faced declines [3]

● 本报记者 孟培嘉 乔翔 恒瑞医药领航创新药出海、海澜之家加速海外业务拓展、埃斯顿深化全球化布局……今年以来，随着港 股IPO市场持续回暖、制度创新不断深化，内地优质企业赴港上市热潮涌动，一批批优质江苏企业正以 扎实的业务根基与前瞻的国际视野，积极对接香港资本市场。数据显示，今年1-8月江苏已有11家企业 成功登陆港股、超过20家正在排队候场，呈现出一派踊跃布局、乘势而上的生动景象。 为助力企业赴港上市、抓住国际资本市场发展机遇，9月15日，由中国证券报、江苏省委金融办联合主 办的"通向新机遇之路——港股IPO专业研培"在江苏省苏州市举行。来自券商、律所等机构的多位资深 专家围绕港股最新政策、上市实务、合规风控等关键环节，为与会江苏企业带来一场系统、深入、可操 作性强的专题培训，助力"江苏板块"在国际资本市场上扬帆起航、行稳致远。 多重因素催生赴港上市潮 今年以来，A股、港股联袂上涨，"中国资产"全球瞩目。作为内地企业联系国际资本市场的重要桥梁， 港股市场今年以来呈现出诸多新变化，其中内地企业赴港上市高潮迭起，行业龙头纷纷递表、"A+H"阵 营频频扩围颇受关注。 数据显示，今年前8个月港交所新股融资额达13 ...

Core Viewpoint - The Chinese innovative drug sector has shown remarkable performance in the capital market this year, driven by record-high business development (BD) amounts for overseas expansion and a rapid growth in domestic revenue, indicating a shift from a "cash-burning" model to a "cash cow" model [1][2]. Group 1: Domestic Demand - The demand for high-quality innovative drugs in China is continuously being released, with A-share innovative drug companies achieving a revenue of 28.69 billion yuan in the first half of the year, a year-on-year increase of approximately 42% [2]. - Leading companies like Heng Rui Medicine reported a 14.5% increase in innovative drug sales revenue to 7.57 billion yuan, primarily from the domestic market [2]. - Other companies such as Bai Jie Shen Zhou and Yi Fan Medicine also reported significant revenue growth, with Bai Jie Shen Zhou's flagship product achieving a 36.5% increase in sales [3]. Group 2: Policy Support - The Chinese government has been actively supporting the development of innovative drugs, with 149 innovative drugs included in the national medical insurance directory since 2018 [4]. - The National Healthcare Security Administration has indicated that by May 2025, the cumulative payment for negotiated drugs will reach 410 billion yuan, driving related drug sales to exceed 600 billion yuan [4]. - New policies are being introduced to address pricing and reimbursement challenges for innovative drugs, including the establishment of a commercial health insurance directory for innovative drugs [5]. Group 3: Research and Development Investment - Despite revenue growth, many innovative drug companies are increasing their R&D investments, creating a positive cycle of revenue growth leading to increased R&D and a rich pipeline [7]. - Heng Rui Medicine invested 3.87 billion yuan in R&D, with over 100 innovative products in clinical development [7]. - The overall trend indicates that companies are focusing on building a robust pipeline to sustain future revenue growth [7]. Group 4: Global Positioning - China currently holds nearly 30% of the global drug R&D market share, with a significant number of first-in-class drug pipelines [8]. - The country has become an important source of global pharmaceutical innovation, with a notable increase in technology licensing and overseas expansion [8]. - The past years of investment during the "innovation drug bubble" period are expected to yield significant results in the coming years [8].

Core Viewpoint - BeiGene's stock has shown significant growth this year, with a year-to-date increase of 99.95%, indicating strong market performance and investor interest [1][2]. Group 1: Stock Performance - As of September 15, BeiGene's stock price reached 321.96 CNY per share, with a trading volume of 8.29 billion CNY and a turnover rate of 2.27%, resulting in a total market capitalization of 496.04 billion CNY [1]. - The stock has experienced a 1.25% increase over the last five trading days, a 32.49% increase over the last 20 days, and a 28.58% increase over the last 60 days [1]. - The company has appeared on the "龙虎榜" (a stock trading list) once this year, with the most recent appearance on September 2 [1]. Group 2: Financial Performance - For the first half of 2025, BeiGene reported a revenue of 17.518 billion CNY, representing a year-on-year growth of 46.03%, and a net profit attributable to shareholders of 450 million CNY, which is a 115.63% increase compared to the previous period [2]. - The number of shareholders decreased by 3.90% to 23,300 as of June 30, 2025, while the average number of circulating shares per person increased by 4.11% to 4,976 shares [2]. Group 3: Shareholder Composition - As of June 30, 2025, the fourth largest shareholder is 中欧医疗健康混合A (China Europe Medical Health Mixed A) with 4.8254 million shares, an increase of 1.2436 million shares from the previous period [2]. - 万家优选 (Wanjia Youxuan) is the sixth largest shareholder with 3 million shares, a decrease of 500,000 shares [2]. - 新进股东 (new shareholder) 南方中证500ETF (Southern CSI 500 ETF) holds 1.7259 million shares [2].